Komparasi Kualitas Hidup Pasien Artritis Gout pada Penggunaan Allopurinol dan Febuxostat

Abstract

Introduction: Gout arthritis is a chronic metabolic disorder that significantly impairs patients' functional status and health-related quality of life (HRQoL). While most studies focus on biochemical targets, such as serum urate levels, evidence comparing patient- reported outcomes between standard urate-lowering therapies (ULTs) remains limited. This study aims to compare the HRQoL of patients with gout treated with allopurinol and Febuxostat. Methods: An observational analytic study with a cross-sectional design was conducted at the Rheumatology Clinic of Adam Malik General Hospital. Fifty patients with chronic gout (25 using Allopurinol and 25 using Febuxostat for at least three months) were recruited. HRQoL was assessed using the Short Form-36 (SF-36) instrument, encompassing the Physical Component Summary (PCS) and Mental Component Summary (MCS). Data were analyzed using the Mann-Whitney U test. Results: The Febuxostat group exhibited significantly higher physical quality of life, with a median PCS score of 71.90 (48.57–92.38) compared to 62.38 (48.57–82.86) in the Allopurinol group (p = 0.020). Conversely, no significant difference was observed in the mental component, with median MCS scores of 71.42 and 72.85 for the Febuxostat and Allopurinol groups, respectively (p = 0.845). The presence of comorbidities, particularly hypercholesterolemia (64–84%) and nephropathy (32% in the Febuxostat group), was prevalent among the subjects. Conclusion: Patients treated with Febuxostat reported has superior physical quality of life compared to those on Allopurinol, whereas mental well-being remained comparable between both therapies. These findings suggest that Febuxostat may offer additional functional benefits beyond mere urate reduction. Keywords: Gout; Allopurinol; Febuxostat; Quality of Life; SF-36